Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval

On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT). Also Read: Sanofi’s Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows. Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not eligible for transplant. This decision marks the third approved indication ...